semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Anemia Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Diagnosis of CLL according to the National Cancer Institute (NCI)/Internal Workshop on Chronic Lymphocytic Leukemia (IWCLL) or small lymphocytic lymphoma (SLL) according to the World Health Organization (WHO) criteria; this includes previous documentation of Biopsy-proven small lymphocytic lymphoma or Diagnosis of CLL according to the NCI/IWCLL as evidenced by all of the following Peripheral blood lymphocyte count of greater than 5 x 10^9/L Immunophenotype consistent with CLL defined as The predominant population of lymphocytes share both B-cell antigens (cluster of differentiation [CD]19, CD20 [typically dim expression], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc) Clonality as evidenced by kappa or lambda light chain restriction (typically dim immunoglobulin expression) Negative FISH analysis for t(11;14)(immunoglobulin heavy locus [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy (e.g. marrow aspirate) or negative immunohistochemical stains for cyclin D1 staining on involved tissue biopsy (e.g. marrow aspirate or lymph node biopsy) No prior chemotherapy, Bruton's tyrosine kinase (BTK) inhibitor therapy, or monoclonal anti-body therapy for treatment of CLL or SLL Has met at least one of the following indications for treatment
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pyruvate Kinase Deficiency Congenital Non-Spherocytic Hemolytic Anemia Patients of all ages with biochemically or genetically diagnosed PKD Patients with a hemolytic anemia AND a family member with genetically diagnosed PKD The participant or the guardian of the participant is willing and able to give written informed consent and/or assent  The participant or the guardian of the participant is unwilling or unable to give written informed consent and/or assent
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Neoplasm Anemia Age > 18 years Diagnosed with colonic or rectal adenocarcinoma Defined date of operation at least 14 days from recruitment to study Confirmed anemia Females of child bearing age must agree to use a medically accepted form of contraceptive  Patient's who are unable to consent Recognized allergy or intolerance of the study drug or excipients Patients with previous or current hematological disease that in the investigators' opinion would confound the diagnosis of anemia
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypoxia Sleep Apnea Obstructive Sleep Apnea Healthy subject Subject aged of 18 years-old at least Diagnostic AHI<15/h and <5% of total sleep time spent with a SaO2<90% Free and informed consent signed Subject covered by social security Negative pregnancy test  Subject with a medical pathology (respiratory, cardiovascular, renal, metabolic, neurological...) Tobacco consumption > 5 cigarettes/days Alcohol consumption > 3 units/days (1 unit=1 drink) Subject under trusteeship or guardianship Subject unaffiliated with the social security Person deprived of their liberty, adult protected by laws, person hospitalized Ongoing participation in another clinical research study Subject non-cooperative or respectful of obligations inherent in the participation in the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Hemophilia A Hemophilia B Von Willebrand's Disease patients with bleeding disorders  none
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Renal Failure patients presenting to the intensive care unit with a diagnosis of acute renal failure (defined as a 1.5 fold increase in plasma Creatinine level compared to baseline)  Age<18 years Hemodialysis or continuous renal replacement therapy(CRRT) Untreated obstructive uropathy Pulmonary emboli
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.25-999.0,  Fanconi Anemia Severe Marrow Failure Myelodysplastic Syndrome (MDS) Acute Myelogenous Leukemia (AML) Patients must have a diagnosis of Fanconi anemia Patients must have one of the following hematologic diagnoses: 1. Severe Aplastic Anemia (SAA), with bone marrow cellularity of <25% OR Severe Isolated Single Lineage Cytopenia and at least one of the following features: 1. Platelet count <20 x 109/L or platelet transfusion dependence* 2. ANC <1000 x 109/L 3. Hgb <8 gm/dl or red cell transfusion dependence* 2. Myelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification 3. Acute Myelogenous Leukemia (untreated, in remission or with refractory or relapsed disease) Donors will be either human leukocyte antigen (HLA) compatible unrelated or HLA-genotypically matched related donors (no fully matched sibling donor) Patients and donors may be of either gender or any ethnic background Patients must have a Karnofsky adult, or Lansky pediatric performance scale status > 70% Patients must have adequate physical function measured by: 1. Cardiac: asymptomatic or if symptomatic then 1) left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise or 2) Shortening Fraction > 29% 2. Hepatic: < 5 x upper limit of normal (ULN) alanine transaminase (ALT) and < 2.0 mg/dl total serum bilirubin. 3. Renal: serum creatinine <1.5 mg/dl or if serum creatinine is outside the normal range, then CrCl > 50 ml/min/1.73 m2 4. Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted Each patient must be willing to participate as a research subject and must sign an informed consent form Female patients and donors must not be pregnant or breastfeeding at the time of signing consent. Women must be willing to undergo a pregnancy test prior to transplant and avoid becoming pregnant while on study  Active CNS leukemia Female patients who are pregnant (positive serum or urine HCG) or breast-feeding Active uncontrolled viral, bacterial or fungal infection Patient seropositive for HIV-I/II; HTLV -I/II
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Liver Cirrhosis Signed written informed consent Dignosis of liver cirrhosis (clinical or by liver biopsy) Admission due to variceal bleeding occurred 5 to 42 days prior and standard treatment for secondary prophylaxis failed Confirmed splenorenal shunt, gastrorenal shunt or paraesophageal vein Sum of targeted SPSS diameters greater than half the diameter of portal vein Child-Pugh score ≤13  Hepatic carcinoma and/or other malignancy diseases Portal vein thrombosis (≥50% of the lumen) Budd-Chiari syndrome Other spontaneous portosystemic shunts Sepsis Spontaneous bacterial peritonitis Uncontrollable hypertension Serious cardiac or pulmonary dysfunction Renal failure With TIPS contraindications
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Healthy 35 or 55-75 years of age General Good health Without diagnosed atherosclerotic disease Without metabolic or inflammatory disease Do not use antioxidant vitamin supplementation Do not use anti-inflammatory medication within last 2 weeks Do not use steroidal substances within past 2 weeks Participants on medications (not listed in the  ) will take medication as normal on all days of study visits Current smoker Severe obesity (BMI>40 kg/m2) Blood pressure greater than 140/90 mmHg Diabetes (fasting glucose >110 mg/dl) Hyperlipidemia (total cholesterol >240 mg/dl) Inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, etc) Diagnosed atherosclerotic heart disease Diagnosed cardiac arrhythmia Bacterial, viral or upper respiratory infection within past 1 month
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Autoimmune Hemolytic Anemia Patients diagnosed with primary warm Autoimmune Hemolytic Anemia (wAIHA) Naive of treatment for hemolytic anemia or in relapse Older than 16 Able to understand written and spoken French who have provided written informed consent for Persons without auto-immune disease, cancer or active infection Older than 16 Able to understand written and spoken French who have provided written informed consent  Cold agglutinin disease Pregnancy Persons without national health insurance
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sepsis ICU patients Adults Sepsis as defined by at least two systemic inflammatory response syndrome and receipt of antimicrobial therapy Cardiopulmonary dysfunction as defined shock or respiratory failure  Inability to obtain consent Greater than 48 hours since initially met Allergy to furosemide AND bumetanide Rhabdomyolysis with creatinine kinase > 5000 U/L Hypercalcemia with calcium >11 mg/dL Diabetic Ketoacidosis requiring continuous insulin infusion Tumor Lysis Syndrome diagnosed clinically Pancreatitis diagnosed clinically Chronic Hypoxic Respiratory Failure with Home Oxygen Use of FiO2≥0.3 Chronic ventilator dependence
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.083-18.0,  Hemolytic Uremic Syndrome of Childhood Pediatric patient (1 month-18 years old) Affected by STEC-HUS defined by  Thrombocytopenia (<150 000/mm3) Mechanic hemolytic anemia (Hemoglobin < 10g/dL, haptoglobin <LLN, lactate dehydrogenase (LDH) >upper limit of normal (ULN) and/or bilirubin > ULN, presence of schizocytes) ARF defined by an estimated Schwartz 2009 creatinin clearance <75ml/min/1,73m² With prodromal diarrhea and/or presence of an enterohemorrhagic strain of Escherichia Coli and/or identification of the Stx 1 or 2 genes in the stool sample or rectal swab Written consent of the 2 parents Female patients of childbearing potential must be practicing an effective, reliable and medically acceptable contraceptive regimen during the entire duration of the study and 5 months after the end of the participation  Neonatal HUS Malignancy Known HIV infection Pregnancy or lactation Identified drug exposure-related HUS Infection-related HUS Known systemic lupus erythematosus or antiphospholipid antibody positivity or syndrome Patient already enrolled in a drug trial Patient with ongoing meningococcal infection Patient affected by aHUS or family history of aHUS
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Obstructive Sleep Apnea (OSA) Aged 18+ Diagnosed with OSA by a practicing sleep physician  Patients with a known history of Cerebrospinal fluid leak, abnormalities of the cribriform plate, head trauma and/or pneumocephalus Patients with pathologically low blood pressure, pneumothorax, a previous history of pneumothorax, or dehydration Patient with bypassed upper airway Other significant sleep disorder(s) (e.g. periodic leg movements, insomnia, central sleep apnea) Previous use of a bi-level device with-in the last 2 years (from enrolment date) Patients with respiratory failure, bullous lung disease or COPD (Chronic Obstructive Pulmonary Disease) Patients with obesity hypoventilation syndrome or congestive heart failure Patients that require supplemental oxygen with their CPAP (Continuous Positive Airway Pressure) device Patients with implanted or life-supporting electronic medical devices (e.g. cardiac pacemakers)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thrombotic Microangiopathies Are at least age 18 at screening (Visit 1) 2. Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP 3. No clinically apparent alternative explanation for thrombocytopenia and anemia  Had eculizumab therapy within three months prior to screening 2. Have STEC-HUS 3. Have a positive direct Coombs test 4. Have an active systemic bacterial or fungal infection requiring antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bacteremia Patient is in the ICU at time the blood culture result reported as positive AND Patient has a positive blood culture with pathogenic bacteria  Patient already enrolled in the trial Patient has severe immune system compromise, as defined by: absolute neutrophil count <0.5x109/L; or is receiving immunosuppressive treatment for solid organ or bone marrow or stem cell transplant Patient has syndrome with well-defined requirement for prolonged treatment infective endocarditis osteomyelitis/septic arthritis undrainable/undrained abscess unremovable/unremoved prosthetic-associated infection Patient has a single positive blood culture with a common contaminant organism according to Clinical Laboratory & Standards Institute (CLSI) Guidelines: coagulase negative staphylococci; or Bacillus spp.; or Corynebacterium spp.; or Propionobacterium spp.; or Aerococcus spp.; or Micrococcus spp Patient has a positive blood culture with Staphylococcus aureus Patient has a positive blood culture with Candida spp. or other fungal species